← All trials
NCT03571724
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 28, 2018
- Primary completion
- Oct 28, 2018
- Completion date
- Mar 28, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 140
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- 22nd Century Limited, LLCLead sponsor
- CelerionOverall official - principal investigator
- CelerionCollaborator
- High Point Clinical Trial CenterOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.